China Re's private placement receives registration approval
China Re said its private placement has received registration approval.
Related stories
Dashenlin Pharmaceutical Q3 Net Profit Rises 21.7% Y/Y
M impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
Haleon CEO Says China Centrum OTC Issue May Persist Through 2027
Haleon is working to mitigate the China Centrum OTC issue through portfolio changes in China.
L impact | EQUITY | Oct 29, 2026, 09:16 AM UTC
KWAP Acquires 250,000 KPJ Healthcare Shares
Kumpulan Wang Persaraan (Diperbadankan) acquired 250,000 shares in KPJ Healthcare.
M impact | EQUITY | Oct 29, 2026, 09:15 AM UTC
One Planet Partners Launches Maiden PE Fund, Partners With Japan’s SMTB
The India-focused firm targets deployment of over ₹3,000 crore, with a first close planned by mid-2027. SMTB has made a strategic equity investment.
M impact | EQUITY | Oct 29, 2026, 09:15 AM UTC
Zhejiang Dingli Machinery Q3 Net Profit Rises 10.3% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:15 AM UTC
Zhejiang Dingli Machinery Q3 Net Profit Rises 10.3% Y/Y
M impact | EQUITY | Oct 29, 2026, 09:15 AM UTC